about
Genetics and neuropathology of Huntington's diseaseHighly resolved in vivo 1H NMR spectroscopy of the mouse brain at 9.4 T.Pathogenesis of inclusion bodies in (CAG)n/Qn-expansion diseases with special reference to the role of tissue transglutaminase and to selective vulnerability.Developing standardized behavioral tests for knockout and mutant mice.Specific reactions of different striatal neuron types in morphology induced by quinolinic acid in rats.Integration-independent Transgenic Huntington Disease Fragment Mouse Models Reveal Distinct Phenotypes and Life Span in Vivo.DNA instability in postmitotic neurons.Compensatory changes in the ubiquitin-proteasome system, brain-derived neurotrophic factor and mitochondrial complex II/III in YAC72 and R6/2 transgenic mice partially model Huntington's disease patients.Cognitive dysfunction in Huntington's disease: mechanisms and therapeutic strategies beyond BDNF.Comparison of huntingtin proteolytic fragments in human lymphoblast cell lines and human brain.Sustained induction of neuronal addition to the adult rat neostriatum by AAV4-delivered noggin and BDNF.Regulation of Neuronal Survival by Nucleophosmin 1 (NPM1) Is Dependent on Its Expression Level, Subcellular Localization, and Oligomerization Status.Aggregation behavior of chemically synthesized, full-length huntingtin exon1.Molecular basis of genetic heterogeneity: role of the clinical neurologist.Neurocardiac dysregulation and neurogenic arrhythmias in a transgenic mouse model of Huntington's disease.Motor deficits associated with Huntington's disease occur in the absence of striatal degeneration in BACHD transgenic mice.Metabolic and glutamatergic disturbances in the Huntington's disease transgenic mouse.Nonlinear decrease over time in N-acetyl aspartate levels in the absence of neuronal loss and increases in glutamine and glucose in transgenic Huntington's disease mice.Reduced Expression of Foxp1 as a Contributing Factor in Huntington's Disease.Cardiac Fas-Dependent and Mitochondria-Dependent Apoptotic Pathways in a Transgenic Mouse Model of Huntington's Disease.In vitro (CTG)*(CAG) expansions and deletions by human cell extracts.
P2860
Q27023050-016487B9-7F35-4B15-B89C-E92834602D7BQ30954808-9128EBCE-9916-4E65-8466-83F5629A8601Q33536410-27DF40B7-87B1-4297-B4D6-86AE997BAF07Q34282779-88816FF1-F2FE-4B47-A4AD-3EE2A35D2EFAQ35121495-CD7C5697-3690-42C4-92D4-6447E41E4704Q35905407-02E09D0C-5A89-44FD-BCCE-D3C1A68F3A1CQ36491349-D2F13804-CD5A-4F9E-A496-E4B02E474994Q36916483-F03A2DA7-0C9E-4AB5-8BC3-E87B6F136ACFQ38928777-6164C6A5-9117-40B3-B9E2-A0004E9023DBQ40721441-9E142FAD-94C8-49F0-931B-6EEA25BFE710Q40763042-E4EB881A-5616-4B95-88CE-841F51F56494Q41161869-78A60EDB-23E8-4EC9-97DC-38A27F6F0AEFQ41513084-BC1A1522-8ED3-48E8-92BF-7DF69F68EFBCQ41735698-9E5992A2-A9A3-4510-BBEA-F44B54088A07Q45289568-E03EE3A3-2C09-4474-AD2B-707ECE316815Q45293567-A7FA3C2C-7DE8-4442-AB0D-C14E9AC4B65FQ45299857-AE5C1B95-CCDC-48DD-B99A-ED8DBDD9818EQ45300316-DD80024A-B122-490F-9908-A0DCF33D59A4Q45302345-3F60311B-EBA7-45C5-81C5-564E528C8EA0Q45304916-4F05F760-7B14-4377-BE5C-34B8F834A38BQ52937253-A9720A74-F6EC-47CA-9BE8-4FE40E78EB66
P2860
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Transgenic models of Huntington's disease.
@en
type
label
Transgenic models of Huntington's disease.
@en
prefLabel
Transgenic models of Huntington's disease.
@en
P2093
P356
P1476
Transgenic models of Huntington's disease.
@en
P2093
P304
P356
10.1093/HMG/6.10.1633
P577
1997-01-01T00:00:00Z